Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health (NASDAQ: HROW) announced a study published in the AANA Journal demonstrating the effectiveness of its MKO Melt® troche as a non-opioid alternative for IV sedation in cataract surgeries. The study involved 107 patients, comparing MKO Melt to traditional sedation methods. Findings indicated comparable comfort levels between both sedation methods, promoting MKO Melt for patients, especially those with needle-phobia. The MKO Melt has been used in over 250,000 cataract surgeries and is available for purchase through ImprimisRx.
Harrow Health (NASDAQ: HROW) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. CEO Mark Baum and CFO Andrew Boll will present a corporate overview, with the management team available for one-on-one meetings. The pre-recorded presentation will be accessible to registered attendees from November 23 until December 3. Additionally, a replay of the conference presentation will be available for approximately 90 days on Harrow’s website.
Harrow Health (NASDAQ: HROW) reported exceptional financial results for Q3 2020, marking the best quarter in its history. Revenues increased month-over-month, achieving record gross margins and adjusted EBITDA. CEO Mark L. Baum expressed optimism about a continuous upward revenue trend heading into 2021, anticipating potential value inflection events. The company primarily focuses on ophthalmology through ImprimisRx and owns significant stakes in several pharmaceutical entities. A conference call discussing these results will be held on Nov. 9, 2020.
Harrow Health (NASDAQ: HROW) will announce its third quarter 2020 financial results after the market closes on November 9, 2020. A conference call will follow at 4:45 p.m. EST, providing an overview of the quarter and future outlook. Investors can access a press release and the company's Letter to Stockholders on its Investor Relations website. The call is intended for analysts to engage with the management team. Replay options for the call will be available until December 9, 2020, for dial-in listeners and until February 9, 2021, for webcast listeners.
Harrow Health (NASDAQ: HROW) will attend Lake Street’s 4th Annual Best Ideas Growth Conference on September 17, 2020, via a virtual platform. CEO Mark L. Baum and CFO Andrew Boll will be available for one-on-one meetings with investors throughout the day to discuss business updates. Interested parties should contact their Lake Street representative to arrange meetings or email conference@lakestreetcm.com for more information. Harrow Health owns a portfolio of healthcare businesses focused on patient-first solutions.
Harrow Health, Inc. (NASDAQ: HROW) announced its second quarter 2020 results, reporting a swift recovery post-COVID-19 impact. CEO Mark L. Baum highlighted record-high revenue days in Q3, attributed to effective product formulations and a new partnership with EyePoint Pharmaceuticals to market DEXYCU®. The company anticipates significant catalysts from Eton, Surface, and Melt in the coming months, bolstering optimism for shareholders.
Harrow Health (NASDAQ: HROW) will release its second quarter 2020 financial results on August 10, 2020, following the market close. A conference call is scheduled for 5:00 PM EDT to discuss these results and recent business developments. The press release will also include a link to the second quarter Letter to Stockholders, available on the Investor Relations website. A replay of the conference call will be accessible until September 10, 2020, with a webcast replay available until November 10, 2020.
Harrow Health (NASDAQ: HROW) announced positive findings from a randomized eye study conducted by its subsidiary ImprimisRx. The study compared patient outcomes using a combination eye drop versus individual drops post-cataract surgery. Results showed the combination drop, which includes prednisolone acetate, gatifloxacin, and bromfenac sodium, demonstrated similar health outcomes with unanimous patient preference for ease of use. The study, published in Clinical Ophthalmology, highlights ImprimisRx's commitment to improving patient compliance and satisfaction with ocular treatments.
Harrow Health, Inc. (HROW) announced that Florida's optometrists can now prescribe its Klarity-C formulation, a preservative-free 0.1% cyclosporine emulsion, following recent updates to the state’s Formulary of Topical Ocular Pharmaceutical Agents. This product has already been prescribed across all 50 states. ImprimisRx, a subsidiary of Harrow, emphasizes the affordability and accessibility of its formulations without the complexities of prior authorizations or co-pays. Klarity-C has gained recognition at the ASCRS Annual Meeting for its efficacy in treating dry eye conditions.
Harrow Health, Inc. (NASDAQ: HROW) announced its first quarter 2020 results, highlighting its optimistic outlook as segments of the economy recover. CEO Mark L. Baum expressed confidence in the ImprimisRx team's ability to support physicians and improve health outcomes. The company has seen orders resume as customers re-open. Upcoming catalysts and developments are discussed in the Letter to Stockholders. A conference call is scheduled for today at 5:00 p.m. EDT for investors and analysts to engage with management.